Drago F, Dal Bello A, Marino V, Pisati R, Lodola E, Barbieri P
Institute of Pharmacology, University of Catania, Medical School, Italy.
Eur J Clin Pharmacol. 1993;44(5):477-80. doi: 10.1007/BF00315547.
The effects of thymoxamine 0.5% solution and of a placebo solution (mannitol) on the mydriasis induced by ibopamine 1% solution were evaluated in 8 healthy volunteers and 12 patients with eye diseases. One drop of ibopamine was instilled into each eye and 30 min later 1 drop of thymoxamine was instilled into one eye and 1 drop of placebo into the contralateral eye. Pupillary diameter was measured before and 30 min after the instillation of ibopamine, immediately before the treatment with thymoxamine and placebo and 30, 60 and 90 min after the instillation of thymoxamine or of placebo. Within 30 min of treatment, ibopamine had produced a statistically and clinically significant mydriatic effect. In eyes treated with thymoxamine, prompt reversal of mydriasis was observed, the baseline diameter being observed within 60 min. No difference in the time-course of the mydriatic effect was detected between healthy subjects and patients. The pupillary response to thymoxamine was not influenced by the colour of the iris. The tolerability of ibopamine and of thymoxamine was good. No local or systemic adverse events were seen or reported.
在8名健康志愿者和12名眼病患者中评估了0.5%噻吗心安溶液和安慰剂溶液（甘露醇）对1%异波帕胺溶液诱发的散瞳作用。每只眼睛滴入1滴异波帕胺，30分钟后，一只眼睛滴入1滴噻吗心安，对侧眼睛滴入1滴安慰剂。在滴入异波帕胺之前和之后30分钟、在使用噻吗心安和安慰剂治疗前即刻以及在滴入噻吗心安或安慰剂之后30、60和90分钟测量瞳孔直径。在治疗的30分钟内，异波帕胺产生了具有统计学意义和临床意义的散瞳作用。在用噻吗心安治疗的眼睛中，观察到散瞳迅速逆转，在60分钟内观察到基线直径。在健康受试者和患者之间未检测到散瞳作用的时间过程有差异。瞳孔对噻吗心安的反应不受虹膜颜色的影响。异波帕胺和噻吗心安的耐受性良好。未观察到或报告局部或全身不良事件。
